Asuragen & Wave Life Sciences unite for development of HD diagnostics
Category: #health  By Nikita Chaurasia  Date: 2019-11-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Asuragen & Wave Life Sciences unite for development of HD diagnostics

It has been reported that various industry giants across the medical fraternity have been involved in the mergers and collaborations to develop and commercialize the treatments for distinguished disorders and diseases. In a light of this, Asuragen and Wave Life Sciences have come together to develop diagnostics for Huntington’s disease.

Austin based molecular diagnostic company, Asuragen has partnered with Wave Life Sciences, a clinical stage genetic medicines company, for the commercialization and manufacturing of the companion diagnostics for Huntington’s disease. For the record, Huntington’s disease is a disorder which is caused by an expansion od CAG repeats in the HTT gene. This results in the gradual breakdown of nerve cells in the brain whilst completely weakening the survivor’s physical and mental abilities.

As per reliable sources, the diagnostics which Asuragen would develop is built on the experience gathered by Wave via a single- nucleotide polymorphism phasing methodology. Through this alliance, Wave targets to utilize Asuragen’s market dominant repetitive sequence diagnostic know-how to deliver scalable SNP phasing to aid global Phase 3 development programs and future commercialization globally.

Speaking on the matter, Jaya Gopal, the VP of Bioanalytics, Pharmacology, and Biomarker Development at Wave’s reportedly stated that the company’s unison with Asuragen for companion diagnostic development is a perfect fit owing to its in depth understanding and expertise with complex molecular targets. Asuragen’s expanding presence in the neurogenetics testing market is also an add on for the Wave.

Meanwhile, the President and CEO of Asuragen, Matthew McManus cited that the company was pleased to a part of the novel category of potential therapies to render a positive impact on HD. He further added that developing a companion diagnostic for Wave’s represents the advancement of the latter company’s product portfolio.

Estimates claim that Wave have currently been conducting two Phase clinical trials, PRECISION-HD1 and PRECISION-HD 2, for the patients suffering from HD. These trials are assessing WVE-120101 & WVE-120102 oligonucleotides, which are designed to reduce the mutant HTT mRNA record.
 

Source credit: https://finance.yahoo.com/news/asuragen-partners-wave-life-sciences-130000639.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Google sued by Justice Department for illicitly holding monopoly power
Google sued by Justice Department for illicitly holding monopoly power
By Nikita Chaurasia

The U.S. Justice Department has reportedly filed a landmark lawsuit against Google LLC of illegally safeguarding its monopoly in order to dominate the search and advertising vertical. If reports are to be believed, the recent antitrust case against G...

Flybe’s flight services to be revived by Thyme Opco post acquisition
Flybe’s flight services to be revived by Thyme Opco post acquisition
By Nikita Chaurasia

COVID-19 restrictions pushed Flybe into administration in March 2020, putting over 2,400 jobs at risk. The acquisition will allow Flybe to restart its operations as a regional airliner in the U.K. It has been speculated that U.K.-based airline c...

Britain hits an absurdly high average asking price for homes
Britain hits an absurdly high average asking price for homes
By Nikita Chaurasia

Reportedly, the average asking price of houses in Britain has reached an all-time high, with buyers willing to spend more for larger properties after experiencing the COVID-19 lockdown. Sources with relevant information stated that for the first tim...